(Q44010115)

28 November 2017

Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada (English)

1 reference

28 November 2017

1 reference

0 references

1

1 reference

28 November 2017

Andrew J Palmer

2

1 reference

PubMed ID

12036382

28 November 2017

Robert Tam

series ordinal

3

1 reference

28 November 2017

1 January 2002

1 reference

28 November 2017

1 reference

28 November 2017

20 Suppl 1

1 reference

28 November 2017

31-42

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200220001-00004

28 November 2017

0 references

cites work

Epidemiology and clinical presentation of type 2 diabetes

1 reference

12 December 2020

Safety aspects of oral hypoglycaemic agents

1 reference

12 December 2020

1 reference

12 December 2020

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

12 December 2020

Economic evaluations relating to diabetes: a descriptive review and their compliance with guidance

1 reference

12 December 2020

The Mt. Hood challenge: cross-testing two diabetes simulation models

1 reference

12 December 2020

Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes

1 reference

12 December 2020

Epidemiology of diabetes mellitus in Canada

1 reference

12 December 2020

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

1 reference

12 December 2020

The global diabetes model: user friendly version 3.0.

1 reference

12 December 2020

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

1 reference

12 December 2020

Assessment of priority for coronary revascularisation procedures. Revascularisation Panel and Consensus Methods Group

1 reference

12 December 2020

The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective

1 reference

12 December 2020

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

12 December 2020

Cost of acute stroke care in Toronto, Canada

1 reference

12 December 2020

Efficacy of metformin in the treatment of NIDDM. Meta-analysis

1 reference

12 December 2020

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

12 December 2020

Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes

1 reference

12 December 2020

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

1 reference

12 December 2020

Nonionic contrast media: economic analysis and health policy development

1 reference

12 December 2020

Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.

1 reference

12 December 2020

Model of complications of NIDDM. I. Model construction and assumptions.

1 reference

12 December 2020

A short term cost-effectiveness model for oral antidiabetic medicines in Europe

1 reference

12 December 2020

A short term cost-effectiveness model for oral antidiabetic medicines in Europe

1 reference

12 December 2020

10.2165/00019053-200220001-00004

Identifiers

DOI

0 references

Dimensions Publication ID

0 references

1 reference

PubMed ID

12036382